Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis - Scorecard - MDSpire
Advertisement
Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis
Clinical Scorecard: Comprehensive Toxicological Systems Approach Reveals TCDD-Responsive Targets Associated with Immune Dysfunction and Treatment Outcomes in Psoriasis
At a Glance
Category
Detail
Condition
Key Mechanisms
Dysregulation of the IL-23/IL-17 axis, TCDD exposure, immune dysfunction
Target Population
Care Setting
Key Highlights
Identification of 87 overlapping genes between TCDD-related targets and psoriasis-associated genes.
Core target genes LCK, MMP9, CXCR2, PTAFR, and CCNB1 show significant upregulation in psoriatic lesions.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Individuals with psoriasis, particularly those with moderate-to-severe forms.
Higher baseline MMP9 may indicate poorer clinical improvement in biologic therapy.
Genetically predicted triglyceride levels were associated with higher odds of psoriasis, while genetically predicted total fatty acid levels were not, in a two-sample Mendelian randomization analysis.
